Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

GB-1211, first orally available galectin-3 inhibitor as potential treatment for NASH

Aug. 26, 2020

First healthy volunteer dosed in phase I clinical program of IMU-856

Aug. 21, 2020

Topline data presented from phase II study of elobixibat in NAFLD and NASH

Aug. 19, 2020

Jiangsu Vcare Pharmatech discovers JAK inhibitors

Aug. 19, 2020

Gargamel (Zhuhai) Biotech discovers JAK-1 inhibitors

Aug. 18, 2020

SCO-267 improves liver parameters in a mouse model of NAFLD

Aug. 14, 2020

Prometheus and Falk enter global collaboration agreement to develop and commercialize PR-600

Aug. 14, 2020

G protein-coupled receptor 35 modulators discovered at Precision IBD

Aug. 13, 2020

Discovery of SHS-4121705 as a novel mitochondrial uncoupler for the treatment of NASH

Aug. 11, 2020

Results from phase III program of etrolizumab in moderate to severe ulcerative colitis

Aug. 10, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 15, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Rethinking anorexia: A disorder of mind and metabolism
BioWorld Science
Anorexia nervosa (AN) is a complex and severe eating disorder that has long been considered a psychiatric condition driven by distorted body image and maladaptive...